STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 29, 2020	$ 131,449	$ 123,373,793	$ (123,657,829)	$ (152,587)
Balance (in shares) at Feb. 29, 2020	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		83,317		83,317
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		281,978		281,978
Net loss			(457,970)	(457,970)
Balance at May. 31, 2020	$ 131,449	123,739,088	(124,115,799)	(245,262)
Balance (in shares) at May. 31, 2020	131,448,444
Balance at Feb. 28, 2021	$ 131,449	124,684,535	(124,861,827)	(45,843)
Balance (in shares) at Feb. 28, 2021	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		84,967		84,967
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		215,926		215,926
Net loss			(316,283)	(316,283)
Balance at May. 31, 2021	$ 131,449	$ 124,985,428	$ (125,178,110)	$ (61,233)
Balance (in shares) at May. 31, 2021	131,448,444